Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

Autor: Jaap J. Zwaginga, Bronno van der Holt, Peter A. te Boekhorst, Bart J. Biemond, Mark-David Levin, René van der Griend, Anneke Brand, Sonja Zweegman, Hans F.M. Pruijt, Vera M.J. Novotny, Art Vreugdenhil, Marco R. de Groot, Okke de Weerdt, Elisabeth C.M. van Pampus, Tanja M. van Maanen-Lamme, Shulamiet Wittebol, Martin R. Schipperus, Matthijs H. Silbermann, Peter C. Huijgens, Marleen Luten, Rene Hollestein, Jan A.C. Brakenhoff, Jolanda G. Schrama, Fransje A.A. Valster, Gerjo A. Velders, Harry R. Koene

Publikováno v: Haematologica, Vol 100, Iss 3 (2015)

Externí odkaz: https://doaj.org/article/aa9c02bce86b43a7ad184444996b6a14

Rituximab-Pecc Induction Followed By 90y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study

Autor: Pieternella J Lugtenburg, Josée M Zijlstra, Jeanette K Doorduijn, Lara H Böhmer, Marinus van Marwijk Kooy, Mels Hoogendoorn, Henriette W Berenschot, Aart Beeker, Fransje Valster, Harry C. Schouten, Marleen Luten, Henk Hofwegen, Dana A Chitu, Rolf E Brouwer, Gustaaf W van Imhoff

Publikováno v: Blood. 126:2707-2707

Background: Patients with relapsed/ refractory diffuse large B-cell lymphoma (DLBCL) after- or not eligible for autologous stem cell transplantation (ASCT) have a poor prognosis. Treatment with salvage chemotherapy has generally been disappointing. I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ddfb187bf3df961b43f877d381f8ef8c
https://doi.org/10.1182/blood.v126.23.2707.2707

Interim Analysis on a Dutch HOVON Multicenter Randomized Open Label Phase II Trial on 3 Rituximab Dosing Schemes In Chronic ITP Patients

Autor: Okke de Weerdt, Marleen Luten, René van der Griend, Anneke Brand, Ronnie van der Holt, Peter A. W. te Boekhorst, Jaap Jan Zwaginga, Sonja Zweegman, Art Vreughdenhil, Elisabeth C. M. Van Pampus, Bart J. Biemond, P. C. Huijgens, Mark Levin, Harry R. Koene, Rene Hollestein, Hans Pruijt

Publikováno v: Blood, 116(21), 1042-1042
Zwaginga, J J, van der Holt, R, Biemond, B J, Boekhorst, P A W, Levin, M, Vreughdenhil, A, Huijgens, P C, Brand, A, van der Griend, R, Luten, M, Pruijt, H, de Weerdt, O, van Pampus, E, Zweegman, S, Hollestein, R & Koene, H R 2010, ' Interim Analysis on a Dutch HOVON Multicenter Randomized Open Label Phase II Trial on 3 Rituximab Dosing Schemes In Chronic ITP Patients: ' . < http://www.mendeley.com/research/interim-analysis-dutch-hovon-multicenter-randomized-open-label-phase-ii-trial-3-rituximab-dosing-sch >

Abstract 2514 The overall short term effectivity of Rituximab in the treatment of ITP is reported to be around 50%. In most studies the traditional CD20 dosing scheme of 4 weekly interspaced 375 mg/m2 doses is used although other single-arm studies s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91342096607e19be0be834be6df27b24
http://hdl.handle.net/1887/118378

Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction

Autor: Jaap Jan Zwaginga, Peter C. Huijgens, Viera M.J. Novotny, Jean-Louis H. Kerkhoffs, Georgine E. de Greef, Peter A. W. te Boekhorst, Dick J. van Rhenen, Lizzy C.M. van Pampus, Martin R. Schipperus, Anneke Brand, Wim L.J. van Putten, Marleen Luten

Publikováno v: British Journal of Haematology.

Pathogen reduction (PR) of platelet products increases costs and available clinical studies are equivocal with respect to clinical and haemostatic effectiveness. We conducted a multicentre, open-label, randomized, non-inferiority trial comparing the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::92e4ed00268bce74ff3ca3a23bab6da0
https://doi.org/10.1111/j.1365-2141.2010.08227.x

The proteome of red cell membranes and vesicles during storage in blood bank conditions

Autor: Willem J. de Grip, Bregt Roerdinkholder-Stoelwinder, Edwin Lasonder, Marleen Luten, Věra M.J. Novotný, Giel J. C. G. M. Bosman, Harry J Bos

Publikováno v: Transfusion, 48, 5, pp. 827-35
Transfusion, 48, 827-35

Contains fulltext : 70689.pdf (Publisher’s version ) (Closed access) BACKGROUND: During storage of red cells (RBCs) for transfusion, RBCs undergo a number of biochemical and morphologic changes. To be able to identify the mechanisms underlying thes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e9cbd81d08f83e1c23650626ac3bc76
https://pubmed.ncbi.nlm.nih.gov/18346024